In MM, overexpression of factors such as NFκB p65 and BCL-xL contribute to heightened survival, proliferation, and resistance to anti-cancer therapies, and contributes to CAM-DR [40,41]. The gene discussed is BCL2L1; the disease is Miyoshi myopathy.